Everolimus — Drug Intelligence | 32 EU Trials

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

17 Recruiting

9 Completed trials

29 Sponsors

18 Countries

Phase III

Phase II

Phase IV

Phase III: 13 Phase II/III: 2 Phase II: 8 Phase I/II: 1 Phase III/IV: 1 Phase IV: 5 Phase I (Other): 2

Oversight events:

2 serious breaches 3 temporary halts across 3 trials

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 4 Hormone receptor positive HER2 negative breast cancer 2 Breast cancer metastatic 2 Pancreatic neuroendocrine tumour 2 Ovarian cancer 1 Acute graft versus host disease 1 HER2 negative breast cancer 1 Neuroendocrine tumour 1 Renal failure 1 Breast cancer female 1 Meningioma 1 Breast cancer 1

Sponsors using this IMP

Odense University Hospital 3 Institut Gustave Roussy 2 ITM Solucin GmbH 2 Pfizer Inc. 2 Universitair Medisch Centrum Groningen 2 Antwerp University Hospital 1 Arvinas Estrogen Receptor Inc. 1 Centre Hospitalier Regional De Marseille 1 Champalimaud Clinical Centre 1 CHRU De Nancy 1 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Exelixis Inc. 1

All trials

32 total

Individualized everolimus therapy in metastatic breast cancer Pending

2023-505590-33-06 Phase II 1 country Orszagos Onkologiai Intezet
Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE) Pending

2023-509838-19-00 Phase II 1 country Odense University Hospital
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Phase II 5 countries Centre Hospitalier De Versailles
Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending

2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma… Pending

2025-524031-39-00 Phase I (Other) 1 country Instytut Pomnik Centrum Zdrowia Dziecka
ALTERNATION Trial: A Clinical Trial Evaluating Everolimus-Based, Calcineurin Inhibitor-Free Immunosuppression One Year After Liver Transplan… Pending

2025-524312-11-00 Phase III 1 country Medizinische Hochschule Hannover
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 Phase III 7 countries Medica Scientia Innovation Research S.L.; Stemline Therapeutics Inc.
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting

2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Phase II/III 8 countries Exelixis Inc.
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Phase III 14 countries Pfizer Inc.
Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE) Recruiting

2024-520372-10-00 Phase II 1 country Odense University Hospital
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr… Recruiting

2023-508400-38-00 Phase II 1 country CHRU De Nancy
Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad… Recruiting

2023-508093-28-00 Phase II 1 country Odense University Hospital
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting

2023-509334-19-00 Phase III 4 countries Rayzebio Inc.
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting

2022-502154-13-00 Phase III 4 countries Grupo Espanol De Tumores Neuroendocrinos
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
EVIDENT Recruiting

2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
Efficiency of everolimus for the treatment of kidney transplanted patients presenting a rejection Recruiting

2024-513814-37-00 Phase IV 1 country Hospices Civils De Lyon
An experimental study in adults and adolescents who underwent stem cell transplantation and developed a Graft versus Host Disease after ster… Recruiting

2023-505737-26-00 Phase III 4 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting

2023-506027-29-00 Phase III 6 countries Institut Gustave Roussy
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Phase III 4 countries Genentech Inc.

Showing 1–24 of 32 trials

← All drugs A–Z